Ligand Pharmaceuticals Incorporated
LGND
$213.21
-$5.77-2.64%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -129.80% | -61.81% | 2,319.50% | 111.42% | -36.55% |
| Total Depreciation and Amortization | 0.02% | -10.30% | 13.12% | -7.70% | 1.66% |
| Total Amortization of Deferred Charges | 22.68% | 12.85% | 72.44% | -24.05% | -4.85% |
| Total Other Non-Cash Items | 367.86% | 83.20% | -1,320.72% | -33.13% | -67.10% |
| Change in Net Operating Assets | -36.65% | 187.51% | -72.01% | -19.41% | -144.54% |
| Cash from Operations | 6.05% | 250.76% | -17.15% | 162.09% | -189.37% |
| Capital Expenditure | -2,433.33% | 40.00% | 92.99% | 0.00% | 69.94% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -840.25% | 97.17% | -3,281.13% | -304.64% | 113.47% |
| Cash from Investing | -421.14% | 94.88% | -3,213.44% | -317.96% | 112.67% |
| Total Debt Issued | -- | -100.00% | -- | -- | -- |
| Total Debt Repaid | 0.00% | 99.99% | -1,617,842.86% | 0.00% | -16.67% |
| Issuance of Common Stock | -17.68% | -63.88% | 212.44% | 95.14% | -81.19% |
| Repurchase of Common Stock | -6,216.86% | 97.74% | -10,395.86% | 98.37% | -359.48% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 91.90% | -101.18% | 658.22% | 9,829.58% | 39.83% |
| Cash from Financing | -269.66% | -97.97% | 2,631.88% | 415.88% | -123.28% |
| Foreign Exchange rate Adjustments | 92.54% | -47.50% | -117.45% | 116.64% | 168.35% |
| Miscellaneous Cash Flow Adjustments | -- | -- | 202.85% | -3,411.54% | -- |
| Net Change in Cash | -268.30% | -50.42% | 264.36% | 180.93% | -379.90% |